01/06/2015 - 18:29
CHICAGO – Nivolumab and nivolumab plus ipilimumab are superior to ipilimumab alone in first-line metastatic melanoma, results from the phase III CheckMate 067 study suggest.
After a minimum of 9...
Field of Interest: Oncology
Categories:
News Feed: Internal Medicine News - Oncology